Combining the Target Trial and Estimand Frameworks to Define the Causal Estimand: An Application Using Real-World Data to Contextualize a Single-Arm Trial

References

• Austin, P. C. (2016), “Variance Estimation When Using Inverse Probability of Treatment Weighting (IPTW) with Survival Analysis,” Statistics in Medicine, 35, 5642–5655. DOI: 10.1002/sim.7084.
   PubMed Web of Science ®Google Scholar
• Backenroth, D. (2021), “How to Choose a Time Zero for Patients in External Control Arms,” Pharmaceutical Statistics, 20, 783–792. DOI: 10.1002/pst.2107.
   PubMed Web of Science ®Google Scholar
• Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., and Lister, T. A., et al. (2014), “Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification,” Journal of Clinical Oncology, 32, 3059–3068. DOI: 10.1200/JCO.2013.54.8800.
   PubMed Web of Science ®Google Scholar
• Collins, R., Bowman, L., Landray, M., and Peto, R. (2020), “The Magic of Randomization versus the Myth of Real-World Evidence,” The New England Journal of Medicine, 382, 674–678. DOI: 10.1056/NEJMsb1901642.
   PubMed Web of Science ®Google Scholar
• Efron, B., and Tibshirani, R. J. (1993), An Introduction to the Bootstrap, London: Chapman & Hall.
   Google Scholar
• European Medicines Agency European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). (2021), “ENCePP Guide on Methodological Standards in Pharmacoepidemiology.”
   Google Scholar
• European Medicines Agency (2021), “Guideline on Registry-based Studies,” available at https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-registry-based-studies_en-0.pdf
   Google Scholar
• FDA Center for Drug Evaluation and Research (2019a), “Multi-Discipline Review. NDA 212306 XPOVIO (Selinexor),” available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000MultidisciplineR.pdf
   Google Scholar
• FDA Center for Drug Evaluation and Research (2019b), “Multi-Discipline Review. NDA 212018 BALVERSA (Erdafitinib),” available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212018Orig1s000MultidisciplineR.pdf
   Google Scholar
• FDA Center for Drug Evaluation and Research (2019c), “Multi-Discipline Review. BLA 761163 Monjuvi (Tafasitamab-cxix),” available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761163Orig1s000MultidisciplineR.pdf
   Google Scholar
• Flatiron Health database (2020), available at https://flatiron.com/real-world-evidence/
   Google Scholar
• Food and Drug Administration (2018), “Real-World Evidence,” available at https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
   Google Scholar
• Fowler, N. H., Dickinson, M., Dreyling, M., Martinez-Lopez, J., Kolstad, A., Butler, J. P., Ghosh, M., Popplewell, L. L., Chavez, J. C., Bachy, E., Kato, K., Harigae, H., Kersten, M. J., Andreadis, C., Riedell, P. A., Ho, P. J., Pérez-Simón, J. A., Nagle, S. J., Nastoupil, L. J., von Tresckow, B., Ferreri, A. J., Teshima, T., Patten, P., McGuirk, J. P., Petzer, A., Offner, F. C., Viardot, A., Zinzani, P. L., Malladi, R., Bubuteishvili Pacaud, L., Forcina, A., Zia, A., Schuster, S. J., and Thieblemont, C. (2020), “Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial,” Blood, 136, 1–3. DOI: 10.1182/blood-2020-138983.
   PubMed Web of Science ®Google Scholar
• Gatto, N. M., Reynolds, R. F., and Campbell, U. B. (2019), “A Structured Preapproval and Postapproval Comparative Study Design Framework to Generate Valid and Transparent Real-World Evidence for Regulatory Decisions,” Clinical Pharmacology & Therapeutics, 106, 103–115. DOI: 10.1002/cpt.1480.
   PubMed Web of Science ®Google Scholar
• Hampson, L. V., Degtyarev, E., Tang, R., Lin, J., Rufibach, K., and Zheng, C. (2023), Commentary on “Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment” by Levenson et al, Statistics in Biopharmaceutical Research, 15, 23–26. DOI: 10.1080/19466315.2021.1994459.
   Web of Science ®Google Scholar
• Hao, Y., Hsu, W.-C., Parzynski, C. S., Degtyarev, E., Hampson, L. V., Masood, A., and Wu, W.-H. “Comparative Effectiveness of Tisagenlecleucel versus Real-World Standard of Care in Patients with Relapsed/Refractory Follicular Lymphoma,” in Preparation.
   Google Scholar
• Hernán, M. A., and Robins, J. M. (2016), “Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available,” American Journal of Epidemiology, 183, 758–764. DOI: 10.1093/aje/kwv254.
   PubMed Web of Science ®Google Scholar
• ICH (2019), “ICH E9(R1) Addendum on Estimands and Sensitivity Analyses in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials,” Available at https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf
   Google Scholar
• Lash, T. L., Fox, M. P., and Fink, A. K. (2009), Applying Quantitative Bias Analysis to Epidemiologic Data, New York: Springer.
   Google Scholar
• Leyrat, C., Seaman, S. R., White, I. R., Douglas, I., Smeeth, L., Kim, J., Resche-Rigon, M., Carpenter, J. R., and Williamson, E. J. (2019), “Propensity Score Analysis with Partially Observed Covariates: How Should Multiple Imputation be Used?” Statistical Methods in Medical Research, 28, 3–19. DOI: 10.1177/0962280217713032.
   PubMed Web of Science ®Google Scholar
• Link, B. K., Day, B.-M., Zhou, X., Zelenetz, A. D., Dawson, K. L., Cerhan, J. R., Flowers, C. R., and Friedberg, J. W. (2019), “Second-Line and Subsequent Therapy and Outcomes for Follicular Lymphoma in the United States: Data from the Observational National LymphoCare Study,” British Journal of Haematology, 184, 660–663. DOI: 10.1111/bjh.15149.
   PubMed Web of Science ®Google Scholar
• Polito, L., Liang, Q., Pal, N., Mpofu, P., Sawas, A., Humblet, O., Rufibach, K., and Heinzman, D. (2021), “Using the Estimand and the Target Trial Frameworks When Building an External Control Data from Real-World Data: A Case-Study in Oncology,” in IBS ROeS Conference 2021. Available at https://www.conftool.pro/ibs-roes2021/index.php?page=browseSessions&form_session=2
   Google Scholar
• Richardson, W. S., Wilson, M. C., Nishikawa, J., and Hayward, R. S. A. (1995), “The Well-Built Clinical Question: A Key to Evidence-based Decisions,” ACP Journal Club, 123, A12–3.
   PubMedGoogle Scholar
• Salles, G., Schuster, S. J., Fischer, L., Kuruvilla, J., Patten, P. E., von Tresckow, B., Smith, S. M., Jiminez Ubieto, A. I., Davis, K. L., Nagar, S. P., Zhang, J., Bollu, V., Jousseaume, E., Ramos, R., Wang, Y., and Link, B. K. (2021), “A Retrospective Cohort Study of Treatment Outcomes of Adult Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma (ReCORD-FL),” Blood, 138, 1349–1349. DOI: 10.1182/blood-2021-145870.
   Google Scholar
• Sarkozy, C., Maurer, M. J., Link, B. K., Ghesquieres, H., Nicolas, E., Thompson, C. A., Traverse-Glehen, A., Feldman, A. L., Allmer, C., Slager, S. L., Ansell, S. M., Habermann, T. M., Bachy, E., Cerhan, J. R., and Salles, G. (2019), “ Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts,” Journal of Clinical Oncology, 37, 144–152. DOI: 10.1200/JCO.18.00400.
   PubMed Web of Science ®Google Scholar
• Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Pantano, S., Pacaud, L. B., Awasthi, R., Chu, J., Anak, Ö., Salles, G., and Maziarz, R. T. (2019), “Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Ccell Lymphoma,” New England Journal of Medicine, 380, 45–56. DOI: 10.1056/NEJMoa1804980.
   PubMed Web of Science ®Google Scholar
• Stuart, E. A., Lee, B. K., and Leacy, F. P. (2013), “Prognostic Score-based Measures Can Be a Useful Diagnostic for Propensity Score Methods in Comparative Effectiveness Research,” Journal of Clinical Epidemiology, 66, S84–S90.e1. DOI: 10.1016/j.jclinepi.2013.01.013.
   PubMed Web of Science ®Google Scholar
• Tenhunen, O., Lasch, F., Schiel, A., and Turpeinen, M. (2020), “Single-Arm Clinical Trials as Pivotal Evidence for Cancer Drug Approval: A Retrospective Cohort Study of Centralized European Marketing Authorizations between 2010 and 2019,” Clinical Pharmacology & Therapeutics, 108, 653–660. DOI: 10.1002/cpt.1965.
   PubMed Web of Science ®Google Scholar
• Thomas, J., Kneale, D., McKenzie, J. E., Brennan, S. E., and Bhaumik, S. (2021), “Determining the Scope of the Review and the Questions it will Address,” in Cochrane Handbook for Systematic Reviews of Interventions Version 6.2, eds. J. T. Higgins, J. Thomas, J. Chandler, M. Cumpston, T. Li, M. J. Page, V. A. Welch (updated Feb 2021). Available at www.training.cochrane.org/handbook
   Google Scholar
• VanderWeele, T. J., and Ding, P. (2017), “Sensitivity Analysis in Observational Research: Introducing the e-value,” Annals of Internal Medicine, 167, 268–274. DOI: 10.7326/M16-2607.
   PubMed Web of Science ®Google Scholar
• Wang, S. V., Pinheiro, S., Hua, W., Arlett, P., Uyama, Y., Berlin, J. A., Bartels, D. B., Kahler, K. H., Bessette, L. G., and Schneeweiss, S. (2021), “STaRT-RWE: Structured Template for Planning and Reporting on the Implementation of Real World Evidence Studies,” British Medical Journal, 372, m4856. DOI: 10.1136/bmj.m4856.
   PubMedGoogle Scholar
• Zhou, J., Vallejo, J., Kluetz, P., Pazdur, R., Kim, T., Keegan, P., Farrell, A., Beaver, J. A., and Sridhara, R. (2019), “Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration between 2008 and 2016,” Journal of National Cancer Institute, 111, djy130.
   Google Scholar